SCCL
MCID: SML038
MIFTS: 69

Small Cell Cancer of the Lung (SCCL)

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Small Cell Cancer of the Lung

MalaCards integrated aliases for Small Cell Cancer of the Lung:

Name: Small Cell Cancer of the Lung 57
Small Cell Lung Cancer 74 20 58 36 54
Small Cell Lung Carcinoma 29 6 44 17
Lung Small Cell Carcinoma 12 20 15
Small-Cell Cancer of Lung 57 13
Sclc 57 58
Small Cell Neuroendocrine Carcinoma of the Lung 20
Small Cell Carcinoma of Lung 71
Cancer, Lung, Small Cell 39
Carcinoma, Small Cell 71
Oat Cell Lung Cancer 20
Sclc; Sccl 57
Sclc1 57
Sccl 57

Characteristics:

Orphanet epidemiological data:

58
small cell lung cancer
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal dominant


HPO:

31
small cell cancer of the lung:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare respiratory diseases


External Ids:

Disease Ontology 12 DOID:5409
OMIM® 57 182280
KEGG 36 H00013
MeSH 44 D055752
NCIt 50 C4917
SNOMED-CT 67 254632001
ICD10 via Orphanet 33 C34.9
UMLS via Orphanet 72 C0149925
Orphanet 58 ORPHA70573
MedGen 41 C0149925
SNOMED-CT via HPO 68 126713003 263681008
UMLS 71 C0149925 C0262584

Summaries for Small Cell Cancer of the Lung

KEGG : 36 Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Small cell lung carcinoma (SCLC) is a highly aggressive neoplasm, which accounts for approximately 25% of all lung cancer cases. Molecular mechanisms altered in SCLC include induced expression of oncogene, MYC, and loss of tumorsuppressor genes, such as p53, PTEN, RB, and FHIT. The overexpression of MYC proteins in SCLC is largely a result of gene amplification. Such overexpression leads to more rapid proliferation and loss of terminal differentiation. Mutation or deletion of p53 or PTEN can lead to more rapid proliferation and reduced apoptosis. The retinoblastoma gene RB1 encodes a nuclear phosphoprotein that helps to regulate cell-cycle progression. The fragile histidine triad gene FHIT encodes the enzyme diadenosine triphosphate hydrolase, which is thought to have an indirect role in proapoptosis and cell-cycle control.

MalaCards based summary : Small Cell Cancer of the Lung, also known as small cell lung cancer, is related to lung disease and small cell carcinoma of the bladder. An important gene associated with Small Cell Cancer of the Lung is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Small cell lung cancer and MicroRNAs in cancer. The drugs Caffeine and Vinblastine have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and lymph node, and related phenotypes are neoplasm of the lung and endocrine/exocrine gland

Disease Ontology : 12 A lung carcinoma that has material basis in primitive-appearing cells that are smaller than normal cells and is located in the lung.

Wikipedia : 74 Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung,... more...

More information from OMIM: 182280

Related Diseases for Small Cell Cancer of the Lung

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Small Cell Cancer of the Lung via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1300)
# Related Disease Score Top Affiliating Genes
1 lung disease 32.4 TP53 NKX2-1 MIR21 GRP ENO2
2 small cell carcinoma of the bladder 32.4 SYP NKX2-1 ENO2 CHGA
3 lung squamous cell carcinoma 32.1 TUG1 TP53 PTEN PIK3CA CCAT2 B2M
4 adenosquamous carcinoma 31.9 TP53 SYP PTEN PIK3CA NKX2-1
5 squamous cell carcinoma 31.7 TUG1 TP73 TP53 RB1 PTEN PIK3CA
6 melanoma 31.7 TP53 RB1 PTEN PIK3CA MALAT1 HOTAIR
7 lung benign neoplasm 31.6 TP53 SYP RB1 NKX2-1 GRP ENO2
8 in situ carcinoma 31.5 TP53 PTEN PIK3CA AKT1
9 mucinous adenocarcinoma 31.5 TP53 NKX2-1 ALK
10 sarcomatoid carcinoma 31.5 SYP NKX2-1 ENO2 ALK
11 pleomorphic carcinoma 31.5 TP53 NKX2-1 ALK
12 lung large cell carcinoma 31.5 SYP NKX2-1 CHGA
13 thyroid carcinoma 31.4 PTEN PIK3CA NKX2-1 MALAT1 HOTAIR
14 osteogenic sarcoma 31.4 TUG1 TP53 RB1 MALAT1 HOTTIP HOTAIR
15 thymoma 31.3 TP53 SYP NKX2-1 AKT1
16 adenoma 31.3 TP53 SYP PIK3CA CHGA AKT1
17 appendix adenocarcinoma 31.3 SYP CHGA
18 pulmonary adenocarcinoma in situ 31.2 NKX2-1 ALK AKT1
19 lung cancer 31.2 TUG1 TP73 TP53 SYP RB1 PTEN
20 glioblastoma 31.2 TUG1 TP53 RB1 PTEN PIK3CA MIR21
21 renal cell carcinoma, nonpapillary 31.2 TUG1 TP53 PTEN PIK3CA NKX2-1 MIR21
22 sarcoma 31.2 TP53 RB1 PIK3CA HOTAIR ALK AKT1
23 retinitis pigmentosa 11 31.2 TUG1 TP53 PTEN HOTAIR ALK
24 esophageal cancer 31.2 TP73 TP53 RB1 PTEN PIK3CA MIR21
25 diabetes mellitus 31.2 TUG1 TP53 PTEN PIK3CA MALAT1 CHGA
26 testicular cancer 31.2 TP53 PTEN ENO2 B2M
27 bladder cancer 31.2 TUG1 TP53 RB1 PTEN PIK3CA MIR21
28 glioma 31.1 TP53 PTEN PIK3CA MIR21 MALAT1 HOTTIP
29 carcinoid tumors, intestinal 31.1 SYP NKX2-1 ENO2 CHGA
30 carcinoid syndrome 31.1 SYP ENO2 CHGA
31 small cell carcinoma 31.1 TP53 SYP PTEN NKX2-1 GRP ENO2
32 plasmacytoma 31.1 SYP B2M AKT1
33 nasopharyngeal carcinoma 31.0 TP53 PTEN PIK3CA MIR21 MALAT1 HOTAIR
34 pulmonary large cell neuroendocrine carcinoma 31.0 SYP CHGA ALK
35 pituitary adenoma 31.0 MALAT1 HOTAIR CHGA CCAT2
36 kidney cancer 31.0 TP53 PTEN PIK3CA MIR21 MALAT1 HOTAIR
37 brain cancer 31.0 TP73 TP53 SYP PTEN PIK3CA ENO2
38 ovarian cancer 31.0 TUG1 TP73 TP53 RB1 PTEN PIK3CA
39 carcinosarcoma 31.0 TP53 PTEN PIK3CA
40 merkel cell carcinoma 31.0 TP53 SYP RB1 NKX2-1 ENO2 CHGA
41 papilloma 31.0 TP53 RB1 PTEN AKT1
42 pancreatic ductal adenocarcinoma 31.0 TP53 PTEN MIR21 MALAT1 HOTTIP HOTAIR
43 clear cell renal cell carcinoma 30.9 TUG1 TP53 PTEN MIR21 MALAT1 CCAT2
44 thyroid gland medullary carcinoma 30.9 SYP NKX2-1 CHGA
45 thymic carcinoma 30.9 TP53 SYP NKX2-1 ENO2
46 squamous cell carcinoma, head and neck 30.9 TP73 TP53 RB1 PTEN PIK3CA MIR21
47 leukemia, acute myeloid 30.9 TUG1 TP53 PTEN PIK3CA MIR21 MALAT1
48 lymphoma, non-hodgkin, familial 30.9 TP53 PIK3CA MIR21 B2M ALK AKT1
49 thyroid carcinoma, familial medullary 30.9 NKX2-1 MALAT1 CHGA
50 nervous system cancer 30.9 TP53 RB1 MIR21 AKT1

Graphical network of the top 20 diseases related to Small Cell Cancer of the Lung:



Diseases related to Small Cell Cancer of the Lung

Symptoms & Phenotypes for Small Cell Cancer of the Lung

Human phenotypes related to Small Cell Cancer of the Lung:

31
# Description HPO Frequency HPO Source Accession
1 neoplasm of the lung 31 HP:0100526

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Oncology:
small-cell lung cancer

Lab:
3p23-p14 chromosome deletion in tumor

Misc:
sensitive to chemotherapy and radiotherapy

Clinical features from OMIM®:

182280 (Updated 05-Mar-2021)

MGI Mouse Phenotypes related to Small Cell Cancer of the Lung:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.02 AKT1 ALK B2M CHGA NKX2-1 PIK3CA
2 nervous system MP:0003631 9.97 AKT1 ALK B2M CHGA ENO2 GRP
3 neoplasm MP:0002006 9.91 AKT1 ALK B2M NKX2-1 PIK3CA PTEN
4 reproductive system MP:0005389 9.65 AKT1 ALK B2M CHGA NKX2-1 PIK3CA
5 respiratory system MP:0005388 9.28 AKT1 ALK ENO2 GRP NKX2-1 PTEN

Drugs & Therapeutics for Small Cell Cancer of the Lung

Drugs for Small Cell Cancer of the Lung (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 664)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caffeine Approved Phase 4 58-08-2 2519
2
Vinblastine Approved Phase 4 865-21-4 13342 241903
3
Atezolizumab Approved, Investigational Phase 4 1380723-44-3
4
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
5
Ipilimumab Approved Phase 4 477202-00-9
6
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
7
Ceritinib Approved Phase 4 1032900-25-6
8
Vemurafenib Approved Phase 4 918504-65-1 23252090 42611257
9
afatinib Approved Phase 4 850140-72-6, 439081-18-2 10184653
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
12
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
13
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
14
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
15
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
16
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
17 Flurbiprofen axetil Investigational Phase 4 91503-79-6
18 acivicin Phase 4
19
Bilirubin Phase 4 635-65-4 5280352
20
Erlotinib Hydrochloride Phase 4 183319-69-9 176871
21 Endostatins Phase 4 71581480
22 Antirheumatic Agents Phase 4
23 Hormones Phase 4
24 Hormone Antagonists Phase 4
25 Analgesics, Non-Narcotic Phase 4
26 Anti-Inflammatory Agents Phase 4
27 Anti-Inflammatory Agents, Non-Steroidal Phase 4
28 Analgesics Phase 4
29 glucocorticoids Phase 4
30 HIV Protease Inhibitors Phase 4
31
protease inhibitors Phase 4
32 Gastrointestinal Agents Phase 4
33 BB 1101 Phase 4
34 Antineoplastic Agents, Hormonal Phase 4
35 Antiemetics Phase 4
36 Cyclooxygenase Inhibitors Phase 4
37 Anesthetics Phase 4
38 Dexamethasone 21-phosphate Phase 4
39
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
40
Nabilone Approved, Investigational Phase 2, Phase 3 51022-71-0 5284592
41
Ifosfamide Approved Phase 3 3778-73-2 3690
42
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
43
Mesna Approved, Investigational Phase 3 3375-50-6 598
44
Sunitinib Approved, Investigational Phase 3 341031-54-7, 557795-19-4 5329102
45
BCG vaccine Approved, Investigational Phase 3
46
Donepezil Approved Phase 3 120014-06-4 3152
47
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
48
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
49
Epirubicin Approved Phase 3 56420-45-2 41867
50
Amifostine Approved, Investigational Phase 3 20537-88-6 2141

Interventional clinical trials:

(show top 50) (show all 4920)
# Name Status NCT ID Phase Drugs
1 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
2 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
3 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
4 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
5 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
6 A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
7 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
8 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
9 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
10 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
11 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
12 An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation Unknown status NCT01646450 Phase 4 Icotinib
13 A Phase Ⅳ,Open,Multicenter,Single Arm Study to Evaluate the Efficacy of the Combination Conmana With Thalidomide in Patients With NSCLC(Non-Small-Cell-Lung-Cancer) Unknown status NCT02778893 Phase 4 Conmana;Thalidomide
14 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
15 High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study Unknown status NCT02404675 Phase 4 icotinib
16 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
17 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
18 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
19 A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
20 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
21 Safety Study of Nivolumab for Selected Advanced Malignancies in India Completed NCT03444766 Phase 4 Nivolumab
22 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
23 An Open , Single-Center, Single Arm Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After Routine Icotinib Therapy Completed NCT01465243 Phase 4 Icotinib
24 Randomized Cross-over Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC. A Phase IV Study. Completed NCT01848613 Phase 4 Vinorelbine
25 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
26 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
27 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
28 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
29 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
30 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
31 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
32 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
33 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
34 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
35 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
36 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
37 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
38 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
39 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
40 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
41 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
42 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
43 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
44 A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC). Completed NCT03853551 Phase 4 Osimertinib
45 An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed NCT01203917 Phase 4 Gefitinib
46 A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations Completed NCT02514174 Phase 4 Afatinib
47 An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy Completed NCT02208843 Phase 4 Afatinib
48 Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Completed NCT03092986 Phase 4 Paclitaxel;Carboplatin;Cisplatin;Vinblastine Sulfate
49 Pembrolizumab for Metastatic Non-small Cell Lung Cancer (NSCLC) Patients Expressing PD-L1 Who Have Their Own Patient-derived Xenograft (PDX): Comparative Study of Clinical Response and In-vivo Antitumor Response Using Their Humanized CD34 PDX (Hu-CD34 PDX) Recruiting NCT03134456 Phase 4 Pembrolizumab Injection
50 A Multicenter, Low-Interventional Study to Evaluate the Feasibility of a Prospective Clinicogenomic Program Recruiting NCT04180176 Phase 4

Search NIH Clinical Center for Small Cell Cancer of the Lung

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Cisplatin
CISPLATIN PWDR
Teniposide
Topotecan
Topotecan Hydrochloride

Cochrane evidence based reviews: small cell lung carcinoma

Genetic Tests for Small Cell Cancer of the Lung

Genetic tests related to Small Cell Cancer of the Lung:

# Genetic test Affiliating Genes
1 Small Cell Lung Carcinoma 29 RB1

Anatomical Context for Small Cell Cancer of the Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Small Cell Cancer of the Lung:

19
Lung

MalaCards organs/tissues related to Small Cell Cancer of the Lung:

40
Lung, Brain, Lymph Node, Bone, T Cells, Endothelial, Neutrophil

Publications for Small Cell Cancer of the Lung

Articles related to Small Cell Cancer of the Lung:

(show top 50) (show all 31105)
# Title Authors PMID Year
1
Comprehensive genomic profiles of small cell lung cancer. 61 57
26168399 2015
2
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. 61 57
22941189 2012
3
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. 61 57
22941188 2012
4
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. 57
12629553 2003
5
Microsatellite alterations in plasma DNA of small cell lung cancer patients. 57
8782463 1996
6
Definition of a tumor suppressor locus within human chromosome 3p21-p22. 57
1438292 1992
7
Three distinct regions involved in 3p deletion in human lung cancer. 57
1347916 1992
8
An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer. 57
1672284 1991
9
Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. 6
2594029 1989
10
Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers. 57
2536219 1989
11
Localization of human ERBA2 to the 3p22----3p24.1 region of chromosome 3 and variable deletion in small cell lung cancer. 57
2848257 1988
12
Restriction fragment length polymorphism studies show consistent loss of chromosome 3p alleles in small cell lung cancer patients' tumors. 57
2900253 1988
13
Molecular genetics of lung cancer. 57
3289123 1988
14
Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. 57
2825033 1987
15
Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. 57
2892196 1987
16
Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. 57
2821398 1987
17
Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. 57
2821400 1987
18
Loss of heterozygosity for a chromosome 3 sequence presumably at 3p21 in small cell lung cancer. 57
2885082 1987
19
Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. 57
3030544 1987
20
Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. 57
2998591 1985
21
A 3p deletion in small cell lung carcinoma. 57
2982478 1985
22
Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. 57
6089338 1984
23
A unique cell-surface protein phenotype distinguishes human small-cell from non-small-cell lung cancer. 57
6289311 1982
24
A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). 57
6286098 1982
25
Human lung small-cell carcinoma contains bombesin. 57
6285381 1982
26
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). 57
6274023 1982
27
Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. 57
6265067 1981
28
Neuron-specific enolase is produced by neuroendocrine tumours. 57
6111674 1981
29
Cytogenetic effects of cigarette smoke condensates in vitro and in vivo. 57
7333590 1981
30
MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. 47
20508945 2011
31
Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. 61 54
20004564 2010
32
Flow cytometric detection of small cell lung cancer cells with aberrant CD45 expression in micrometastatic bone marrow. 54 61
19674995 2009
33
Caveolin-1 is an important factor for the metastasis and proliferation of human small cell lung cancer NCI-H446 cell. 54 61
19718715 2009
34
[Relationship between vascular endothelial growth factor C expression level and lymph node metastasis in non small cell lung cancer]. 61 54
19080076 2008
35
[Role of the cut-off value of serum neuron-specific enolase in differentiating small cell lung cancer from non-small cell lung cancer]. 61 54
16793621 2006
36
Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. 54 61
15923178 2005
37
Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. 61 54
15205342 2004
38
A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. 61 54
9331137 1997
39
Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1. 61 54
7589398 1995
40
Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line. 54 61
8061113 1994
41
Human aminoacylase-1. Cloning, sequence, and expression analysis of a chromosome 3p21 gene inactivated in small cell lung cancer. 54 61
8394326 1993
42
Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. 54 61
1689190 1990
43
Circular RNA circ_0001287 inhibits the proliferation, metastasis, and radiosensitivity of non-small cell lung cancer cells by sponging microRNA miR-21 and up-regulating phosphatase and tensin homolog expression. 61
33467964 2021
44
Algorithm using Neuron-Specific Enolase and Pro-Gastrin-Releasing Peptide to Increase the Diagnostic Accuracy for Small Cell Lung Cancer. 61
33303722 2021
45
Glycogen phosphorylase B promotes cell proliferation and migration through PI3K/AKT pathway in non-small cell lung cancer. 61
33336613 2021
46
m6 A transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer. 61
32892348 2021
47
Network pharmacology and molecular docking reveal the mechanism of Scopoletin against non-small cell lung cancer. 61
33497736 2021
48
Circ_0000735 enhances the proliferation, metastasis and glycolysis of non-small cell lung cancer by regulating the miR-635/FAM83F axis. 61
33560141 2021
49
LncRNA PART1 promotes cell proliferation and progression in non-small-cell lung cancer cells via sponging miR-17-5p. 61
33368623 2021
50
Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges. 61
33450361 2021

Variations for Small Cell Cancer of the Lung

ClinVar genetic disease variations for Small Cell Cancer of the Lung:

6 (show top 50) (show all 106)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RB1 NM_000321.2(RB1):c.2242G>T (p.Glu748Ter) SNV Pathogenic 13078 rs121913297 13:49039164-49039164 13:48465028-48465028
2 ALK t(2;2)(p23;p21)(hg19 chr2:g.42552694::ochr2:g.29446394) Inversion Pathogenic 487484 2:29446394-42552694
3 RB1 NM_000321.3(RB1):c.1215+1G>A SNV Pathogenic 126832 rs587776783 13:48947629-48947629 13:48373493-48373493
4 RB1 NM_000321.3(RB1):c.1981C>T SNV Pathogenic 13087 rs137853294 13:49033844-49033844 13:48459708-48459708
5 TP53 NM_000546.5(TP53):c.839G>C (p.Arg280Thr) SNV Likely pathogenic 12368 rs121912660 17:7577099-7577099 17:7673781-7673781
6 TP53 NM_000546.5(TP53):c.838A>G (p.Arg280Gly) SNV Likely pathogenic 376658 rs753660142 17:7577100-7577100 17:7673782-7673782
7 TP53 NM_000546.5(TP53):c.700T>C (p.Tyr234His) SNV Likely pathogenic 376691 rs864622237 17:7577581-7577581 17:7674263-7674263
8 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln) SNV Likely pathogenic 376244 rs121913273 3:178936082-178936082 3:179218294-179218294
9 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
10 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
11 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
12 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Likely pathogenic 376473 rs1057519927 3:178936083-178936083 3:179218295-179218295
13 AKT1 NM_005163.2(AKT1):c.49G>A (p.Glu17Lys) SNV Likely pathogenic 13983 rs121434592 14:105246551-105246551 14:104780214-104780214
14 PTEN NM_000314.8(PTEN):c.389G>T SNV Likely pathogenic 376509 rs121909229 10:89692905-89692905 10:87933148-87933148
15 TP53 NM_000546.5(TP53):c.839G>T (p.Arg280Ile) SNV Likely pathogenic 161517 rs121912660 17:7577099-7577099 17:7673781-7673781
16 PIK3CA NM_006218.4(PIK3CA):c.1625A>T (p.Glu542Val) SNV Likely pathogenic 376474 rs1057519927 3:178936083-178936083 3:179218295-179218295
17 PTEN NM_000314.7(PTEN):c.389G>C (p.Arg130Pro) SNV Likely pathogenic 142018 rs121909229 10:89692905-89692905 10:87933148-87933148
18 PIK3CA NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys) SNV Likely pathogenic 31944 rs121913273 3:178936082-178936082 3:179218294-179218294
19 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely pathogenic 217293 rs121913275 3:178936093-178936093 3:179218305-179218305
20 TP53 NM_000546.5(TP53):c.578A>G (p.His193Arg) SNV Likely pathogenic 184979 rs786201838 17:7578271-7578271 17:7674953-7674953
21 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
22 TP53 NM_000546.6(TP53):c.797G>A (p.Gly266Glu) SNV Likely pathogenic 161516 rs193920774 17:7577141-7577141 17:7673823-7673823
23 PIK3CA NM_006218.4(PIK3CA):c.1625A>G (p.Glu542Gly) SNV Likely pathogenic 376475 rs1057519927 3:178936083-178936083 3:179218295-179218295
24 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Likely pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
25 TP53 NM_000546.5(TP53):c.658T>C (p.Tyr220His) SNV Likely pathogenic 376687 rs530941076 17:7578191-7578191 17:7674873-7674873
26 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln) SNV Likely pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
27 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met) SNV Likely pathogenic 233951 rs876660754 17:7578413-7578413 17:7675095-7675095
28 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely pathogenic 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
29 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely pathogenic 13656 rs121913274 3:178936092-178936092 3:179218304-179218304
30 PTEN NM_001304718.2(PTEN):c.-363C>G SNV Likely pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
31 TP53 NM_000546.5(TP53):c.839G>A (p.Arg280Lys) SNV Likely pathogenic 376657 rs121912660 17:7577099-7577099 17:7673781-7673781
32 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
33 TP53 NM_000546.5(TP53):c.487T>G (p.Tyr163Asp) SNV Likely pathogenic 187052 rs786203436 17:7578443-7578443 17:7675125-7675125
34 TP53 NM_000546.5(TP53):c.643A>G (p.Ser215Gly) SNV Likely pathogenic 265337 rs886039484 17:7578206-7578206 17:7674888-7674888
35 TP53 NM_000546.5(TP53):c.857A>G (p.Glu286Gly) SNV Likely pathogenic 376590 rs1057519985 17:7577081-7577081 17:7673763-7673763
36 RB1 NM_000321.2(RB1):c.2117G>T (p.Cys706Phe) SNV Likely pathogenic 376330 rs121913295 13:49037877-49037877 13:48463741-48463741
37 TP53 NM_000546.5(TP53):c.587G>C (p.Arg196Pro) SNV Likely pathogenic 231165 rs483352697 17:7578262-7578262 17:7674944-7674944
38 TP53 NM_000546.5(TP53):c.535C>G (p.His179Asp) SNV Likely pathogenic 376610 rs587780070 17:7578395-7578395 17:7675077-7675077
39 TP53 NM_000546.5(TP53):c.644G>T (p.Ser215Ile) SNV Likely pathogenic 376660 rs587782177 17:7578205-7578205 17:7674887-7674887
40 TP53 NM_000546.5(TP53):c.746G>T (p.Arg249Met) SNV Likely pathogenic 376653 rs587782329 17:7577535-7577535 17:7674217-7674217
41 TP53 NM_000546.5(TP53):c.518T>A (p.Val173Glu) SNV Likely pathogenic 376669 rs1057519747 17:7578412-7578412 17:7675094-7675094
42 TP53 NM_000546.5(TP53):c.578A>T (p.His193Leu) SNV Likely pathogenic 185822 rs786201838 17:7578271-7578271 17:7674953-7674953
43 TP53 NM_000546.5(TP53):c.518T>G (p.Val173Gly) SNV Likely pathogenic 376016 rs1057519747 17:7578412-7578412 17:7675094-7675094
44 TP53 NM_000546.5(TP53):c.535C>A (p.His179Asn) SNV Likely pathogenic 376609 rs587780070 17:7578395-7578395 17:7675077-7675077
45 TP53 NM_000546.5(TP53):c.731G>A (p.Gly244Asp) SNV Likely pathogenic 372785 rs985033810 17:7577550-7577550 17:7674232-7674232
46 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro) SNV Likely pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
47 TP53 NM_000546.5(TP53):c.658T>A (p.Tyr220Asn) SNV Likely pathogenic 376688 rs530941076 17:7578191-7578191 17:7674873-7674873
48 TP53 NM_000546.5(TP53):c.535C>T (p.His179Tyr) SNV Likely pathogenic 127815 rs587780070 17:7578395-7578395 17:7675077-7675077
49 TP53 NM_000546.5(TP53):c.374C>G (p.Thr125Arg) SNV Likely pathogenic 376667 rs786201057 17:7579313-7579313 17:7675995-7675995
50 TP53 NM_000546.5(TP53):c.488A>G (p.Tyr163Cys) SNV Likely pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124

Copy number variations for Small Cell Cancer of the Lung from CNVD:

7 (show top 50) (show all 515)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 15909 1 120235683 147296355 Substitutions and indels small cell lung cancer
2 18774 1 147306435 159745095 Substitutions and indels small cell lung cancer
3 21590 1 159753915 159864147 Substitutions and indels small cell lung cancer
4 21631 1 159879159 167481135 Substitutions and indels small cell lung cancer
5 22562 1 167488767 167515635 Substitutions and indels small cell lung cancer
6 22575 1 167524383 182844003 Substitutions and indels small cell lung cancer
7 22643 1 16801095 16840107 Substitutions and indels small cell lung cancer
8 22724 1 16861959 29150031 Substitutions and indels small cell lung cancer
9 24621 1 182849019 182888703 Substitutions and indels small cell lung cancer
10 24623 1 182893695 194979795 Substitutions and indels small cell lung cancer
11 25853 1 194993223 195074031 Substitutions and indels small cell lung cancer
12 25942 1 195088143 205083387 Substitutions and indels small cell lung cancer
13 27160 1 205088907 205109547 Substitutions and indels small cell lung cancer
14 27163 1 205114395 208124379 Substitutions and indels small cell lung cancer
15 27411 1 208129227 208155879 Substitutions and indels small cell lung cancer
16 27424 1 208162923 222138663 Substitutions and indels small cell lung cancer
17 28412 1 222150063 222281979 Substitutions and indels small cell lung cancer
18 28435 1 222297471 247249719 Substitutions and indels small cell lung cancer
19 31650 1 29155527 30043083 Substitutions and indels small cell lung cancer
20 31718 1 30048807 41173191 Substitutions and indels small cell lung cancer
21 32828 1 39746 16783059 Substitutions and indels small cell lung cancer
22 33011 1 41174800 41175800 Intrachromosomal rearrangement small cell lung cancer
23 33013 1 41178543 42371163 Substitutions and indels small cell lung cancer
24 33099 1 42374208 42375208 Intrachromosomal rearrangement small cell lung cancer
25 33100 1 42376011 42579327 Substitutions and indels small cell lung cancer
26 33116 1 42583395 42584395 Intrachromosomal rearrangement small cell lung cancer
27 33117 1 42584427 44255643 Substitutions and indels small cell lung cancer
28 33294 1 44259752 44260752 Intrachromosomal rearrangement small cell lung cancer
29 33295 1 44260511 44261511 Intrachromosomal rearrangement small cell lung cancer
30 33296 1 44260527 44275323 Substitutions and indels small cell lung cancer
31 33300 1 44279330 44280330 Intrachromosomal rearrangement small cell lung cancer
32 33301 1 44279742 44280742 Intrachromosomal rearrangement small cell lung cancer
33 33302 1 44280303 48578211 Substitutions and indels small cell lung cancer
34 33819 1 48580747 48581747 Intrachromosomal rearrangement small cell lung cancer
35 33821 1 48583227 51275739 Substitutions and indels small cell lung cancer
36 33980 1 51279608 51280608 Intrachromosomal rearrangement small cell lung cancer
37 33981 1 51281079 54467547 Substitutions and indels small cell lung cancer
38 34296 1 54469360 54470360 Intrachromosomal rearrangement small cell lung cancer
39 34297 1 54473247 54557103 Substitutions and indels small cell lung cancer
40 34301 1 54561497 54562497 Intrachromosomal rearrangement small cell lung cancer
41 34302 1 54562083 54649251 Substitutions and indels small cell lung cancer
42 34322 1 54652634 54653634 Intrachromosomal rearrangement small cell lung cancer
43 34323 1 54654159 57627915 Substitutions and indels small cell lung cancer
44 34908 1 57632775 57657135 Substitutions and indels small cell lung cancer
45 34910 1 57661947 72536187 Substitutions and indels small cell lung cancer
46 36221 1 72541191 72583059 Substitutions and indels small cell lung cancer
47 36257 1 72587919 85749039 Substitutions and indels small cell lung cancer
48 37122 1 85755495 85774959 Substitutions and indels small cell lung cancer
49 37129 1 85779879 120230763 Substitutions and indels small cell lung cancer
50 41421 10 17866791 18173655 Substitutions and indels small cell lung cancer

Expression for Small Cell Cancer of the Lung

Search GEO for disease gene expression data for Small Cell Cancer of the Lung.

Pathways for Small Cell Cancer of the Lung

Pathways related to Small Cell Cancer of the Lung according to KEGG:

36
# Name Kegg Source Accession
1 Small cell lung cancer hsa05222
2 MicroRNAs in cancer hsa05206

Pathways related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1 12.74 TP53 RB1 PTEN PIK3CA ALK AKT1
2
Show member pathways
12.69 TP53 RB1 PTEN PIK3CA AKT1
3
Show member pathways
12.68 TP73 TP53 RB1 PIK3CA B2M AKT1
4
Show member pathways
12.62 TP73 TP53 PTEN PIK3CA AKT1
5
Show member pathways
12.54 TP53 RB1 PTEN PIK3CA ALK AKT1
6
Show member pathways
12.32 TP53 PTEN PIK3CA AKT1
7
Show member pathways
12.3 TP73 TP53 RB1 PTEN
8
Show member pathways
12.23 TP53 PTEN PIK3CA AKT1
9 12.21 TP53 PIK3CA MIR21 AKT1
10
Show member pathways
12.15 TP53 RB1 PTEN AKT1
11
Show member pathways
12.14 TP53 RB1 PTEN PIK3CA AKT1
12 12.06 TP53 RB1 PTEN AKT1
13 11.97 TP73 TP53 RB1 PTEN
14 11.96 TP53 RB1 PTEN PIK3CA AKT1
15 11.9 TP53 PTEN PIK3CA AKT1
16 11.82 TP53 RB1 PTEN AKT1
17 11.79 RB1 PTEN AKT1
18 11.77 TP53 RB1 PTEN PIK3CA B2M AKT1
19 11.75 TP53 PTEN AKT1
20 11.67 TP53 PIK3CA AKT1
21 11.63 RB1 PIK3CA AKT1
22
Show member pathways
11.61 TP53 PIK3CA AKT1
23 11.61 TP73 TP53 PTEN PIK3CA AKT1
24 11.58 TP53 PTEN PIK3CA AKT1
25 11.52 TP53 PTEN PIK3CA AKT1
26 11.48 PTEN PIK3CA AKT1
27 11.36 TP53 PTEN PIK3CA AKT1
28 11.22 TP53 RB1 PTEN AKT1
29 11.16 PTEN PIK3CA AKT1
30 10.98 TP53 RB1 PTEN PIK3CA AKT1
31 10.73 TP53 HOTAIR

GO Terms for Small Cell Cancer of the Lung

Biological processes related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.89 TP53 PTEN NKX2-1 MIR21 AKT1
2 negative regulation of cell proliferation GO:0008285 9.85 TP73 TP53 RB1 PTEN MIR21
3 positive regulation of apoptotic process GO:0043065 9.77 TP73 TP53 PTEN MIR21 AKT1
4 negative regulation of epithelial cell proliferation GO:0050680 9.61 RB1 PTEN B2M
5 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.58 RB1 PTEN MIR21
6 anoikis GO:0043276 9.51 PIK3CA AKT1
7 negative regulation of cell size GO:0045792 9.48 PTEN AKT1
8 protein kinase B signaling GO:0043491 9.33 PTEN PIK3CA AKT1
9 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.32 GRP CHGA
10 cellular response to decreased oxygen levels GO:0036294 9.26 PTEN AKT1
11 phosphatidylinositol 3-kinase signaling GO:0014065 9.13 PTEN PIK3CA AKT1
12 cellular response to hypoxia GO:0071456 8.92 TP53 PTEN MALAT1 AKT1

Molecular functions related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 TP73 TP53 SYP RB1 PTEN B2M
2 MDM2/MDM4 family protein binding GO:0097371 9.16 TP73 TP53
3 enzyme binding GO:0019899 9.02 TP53 RB1 PTEN NKX2-1 AKT1

Sources for Small Cell Cancer of the Lung

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....